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Abstracts
Gregory L. Moneta, MD, Section EditorDisparity in Outcomes of Surgical Revascularization for Limb Salvage:
Race and Gender are Synergistic Determinants of Vein Graft Failure
and Limb Loss
Nguyen LL, Hevelone N, Rogers SO, et al. Circulation 2009;119:123-30.
Conclusion: Female gender and black race are risk factors for adverse
events after vein bypass surgery for limb salvage.
Summary: This article represents another of the many interesting post
hoc analyses derived from the PREVENT III, a multicenter clinical trial of
patients undergoing vein bypass for critical limb ischemia (J Vasc Surg
2006;43:742-51). The PREVENT III database represents the largest pro-
spective cohort of patients who underwent surgical treatment for critical
limb ischemia. The database includes 1404 lower extremity vein graft
operations performed for critical limb ischemia at 83 North American
centers. The patients had intensive ultrasound surveillance of the bypass
graft and clinical follow-up for 1 year.
This particular analysis was designed to examine the interactions of race
and gender as they affect graft patency, limb salvage, and mortality. Propor-
tional hazards and propensity scoring was used to examine relationships of
patient demographics to relevant clinical end points. These included peri-
operative events and 1-year outcomes of graft patency, limb salvage, and
patient survival. Propensity score models adjusting for covariants that in-
cluded institution, comorbidities, technical factors, and adjunctive medica-
tions were used to examine associations between race, gender, and out-
comes.
The PREVENT III trial had 249 black patients (131 men and 118
women). Black men were at increased risk for early (30-day) graft failure
(hazard ratio [HR], 2.832; 95% confidence interval [CI], 1.393-5.759; P
.0004). This held true even when analysis was restricted to exclude high-risk
venous conduits. Black patients also had reduced secondary patency (HR,
1.49; 95% CI, 1.08-2.06; P  .016) and reduced limb salvage (HR, 2.02;
95% CI, 1.27-3.20; P  .003) at 1 year. Black women were the most
disadvantaged, with an increased risk of graft thrombosis (HR, 2.02 for
secondary patency; 95% CI, 1.27-3.20; P  .003) and an increased risk for
major amputation (HR, 2.38; 95% CI, 1.18-4.83; P  .016) at 1 year.
Perioperative mortality and 1-year mortality, however, were similar across
race and gender groups.
Comment: It has been previously suggested that African Americans
and women have poorer results with vascular surgery. The findings in this
study are therefore not all that surprising. The authors suggest the data raise
the possibility of an altered response to vein bypass surgery in there sub-
groups. It is certainly not obvious what this biologic response would be.
Nevertheless, the clinical implication is that African American women un-
dergoing vein graft bypass surgery are a particularly high-risk group that may
benefit from very aggressive postoperative surveillance and medical manage-
ment.
General Anesthesia Versus Local Anesthesia for Carotid Surgery
(GALA): A Multicentre, Randomised Controlled Trial
GALA Trial Collaborative Group. Lancet 2008;372:2132-42.
Conclusion: There is no definite difference in outcomes between
general and local anesthesia for carotid surgery.
Summary: Whether carotid endarterectomy under local or general
anesthesia results in a more favorable outcome is a topic of considerable
debate. The General Anesthesia Versus Local Anesthesia for Carotid Surgery
(GALA) trial sought to address the efficacy of local vs general anesthesia in
the prevention of complications of carotid surgery. This was a parallel group,
multicenter, randomized controlled trial of 3526 patients with symptomatic
or asymptomatic carotid stenosis. The patients were derived from 95 centers
in 24 countries. Study participants were randomly assigned to surgery under
general (n  1763) or local (n  1773) anesthesia. The primary outcome
end point was the proportion of patients with stroke (including retinal
infarction), death between randomization and 30 days after surgery, or
myocardial infarction. Analysis was on an intention to treat basis.
The general anesthesia patients sustained 84 (4.8%) outcome events
and the local anesthesia patients had 80 (4.5%). Overall, three events per
1000 patients treated were prevented with local anesthesia (95% confidence
interval, -11 to 17) with a risk ratio of 0.94 (95% confidence interval,
0.70-1.27). There were no differences between those patients undergoing
surgery with local vs general anesthesia with respect to quality of life, length
of hospital stay, or the primary outcome in prespecified subgroups stratified
for age, contralateral carotid occlusion, and baseline surgical risk.Comment: The trial failed to show a convincing difference between
general and local anesthesia with respect to outcomes after carotid surgery.
1626There were no significant differences with regard to perioperative stroke,
myocardial infarction, or death. The results are consistent with other clinical
trials evaluating major surgical procedures that have also failed to show a
convincing benefit for local or regional anesthesia (BMJ 2000;323:1493 and
Lancet 2002;359:1276-82). The surgeon and the anesthesiologist as a team
should use whatever technique they are most comfortable with in perform-
ing carotid surgery.
Deep Vein Thrombosis of Lower Extremity: Direct Intraclot Injection
of Alteplase Once Daily with Systemic Anticoagulation—Results of
Pilot Study
Chang R, Chen CC, Kam A, et al. Radiology 2008;246:619-29.
Conclusion: Daily intraclot injection of a venous thrombus with
alteplase can be an alternative to continuous infusion thrombolytic therapy
for treatment of deep venous thrombosis (DVT).
Summary: An alternative to continuous infusion of lytic agents is to
intermittently lace the thrombus with a thrombolytic agent that binds to
fibrin in the clot and is rapidly cleared from the general circulation. This can
allow the thrombolytic agent to work at the site where it is needed but
minimize the duration of systemic exposure to the thrombolytic agent.
This study prospectively evaluated the outcome of patients with acute
DVT in the lower extremity treated with daily lacing of the thrombus with
alteplase. Alteplase has a high fibrin affinity and therefore continuous infu-
sion of the thrombolytic agent is not required. Twenty patients with first-
onset acute DVT were treated with direct daily lacing of the thrombus with
alteplase with amaximum daily dosage of 50mg/leg and amaximum of four
treatments. Catheters were left in place between treatments. Patients were
also systemically anticoagulated fully. Patients underwent ventilation perfu-
sion (V/Q) scans, which were performed before treatment and during
thrombolytic therapy.
The study comprised 13 men and 7 women, aged 18 to 79 years.
Antegrade blood flow was restored throughout the deep venous system in
16 patients (80%) during thrombolytic therapy. After 6 months of antico-
agulation, 18 patients (90%) had complete resolution of symptoms. There
was rapid clearance of circulating alteplase and recovery of plasminogen
activator inhibitor-1 levels by pharmacokinetic studies 2 hours after ter-
mination of alteplase treatment. A 40% incidence of pulmonary embolism
was documented by V/Q scanning before treatment and a 15% incidence of
asymptomatic pulmonary embolism during thrombolytic therapy. No clin-
ically important pulmonary embolism or serious bleeding occurred during
thrombolytic therapy. During the mean follow-up of 3.4 years, no post-
thrombotic syndrome or recurrent DVT developed in any patient.
Comment: The most obvious practical advantage of this approach is
that patients do not require intensive monitoring of a continuous infusion of
a thrombolytic agent. However, intermittent administration of alteplase
directly into the thrombus does require a substantial time commitment.
Procedure times for the first treatment of an uncomplicated iliofemoral DVT
were 1.5 hours. If there was extensive calf DVT, initial procedure times
could be doubled or almost tripled. Procedure times for subsequent treat-
ments are shorter because catheters are left in place after the initial treatment
and can be exchanged using standard guidewire techniques. Overall, it
appears if one has the catheter skills and time, intermittent administration of
a thrombolytic agent directly into the clot may be a viable alternative tomore
standard continuous infusion techniques.
Determinants of Systemic Vascular Function in Patients with Stable
Chronic Obstructive Pulmonary Disease
Eickhoff P, Valipour A, Kiss D, et al. Am J Resp Crit Care Med 2008;178:
1211-8.
Conclusion: Endothelium-dependent and endothelium-independent
vasodilation is impaired in patients with chronic obstructive pulmonary
disease (COPD).
Summary:COPD is an inflammatory lung disease; however, increasing
data suggest the inflammatory reaction associated with COPD is not re-
stricted to the lung. Patients with stable COPD had increased levels of
systemic inflammatory markers, such as C-reactive protein, compared with
controls. In addition, inflammation associated with COPD appears to in-
creases over time, and systemic inflammation associated with COPD in-
creases during acute exacerbations. Systemic inflammation also contributes
to the development of cardiovascular diseases. It has been observed that
there is an increased risk of cardiovascular morbidity and mortality in
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anism for this remains unknown.
The goal of this study was to assess vascular reactivity as mediated
through both brachial artery flow-mediated (endothelium dependent) and
nitrogen-mediated (endothelium independent) dilatation of the brachial
artery in patients with COPD and controls, and to investigate a potential
relationship between vascular function and airflow obstruction and systemic
inflammation. There were 60 patients with stable COPD studies, of these,
20 were smokers with normal lung function matched for age, sex, and body
weight, and 20 were similarly matched nonsmokers. Patients with known
cardiovascular morbidities were excluded. Systemic inflammatory markers,
including interleukin-6, C-reactive protein, and fibrinogen, were measured.
In patients with stable COPD, flow-mediated and nitrogen-mediated
dilatation of the brachial artery was impaired compared with smoking and
nonsmoking controls. Levels of inflammatory markers such as fibrinogen
and interleukin-6 were higher in COPD patients than in controls. Stepwise
multiple regression analysis showed that baseline brachial diameter, C-
reactive protein level, leukocyte count, blood glucose level, age, sex, and
percentage of predicted forced expiratory volume in 1 second were indepen-
dent predictors of flow-mediated dilatation. Pack-years of smoking did not
have a relationship with flow-mediated dilatation. Baseline brachial artery
diameter was the only independent predictor of nitrogen-mediated dilata-
tion in patients with COPD.
Comment: This study tells us that impaired flow-mediated dilatation is
strongly related to systemic inflammation in airway obstruction. Systemic
inflammation is also related to atherosclerosis. Cardiovascular morbidity and
endothelial dysfunction as measured by flow-mediated brachial artery dila-
tation is an early sign of atherosclerotic risk. Therefore, the study suggests a
link between COPD and atherosclerosis, with both mediated by way of
systemic markers of inflammation. Diabetes also may be a chronic inflam-
matory disease. The precise elements of chronic inflammation that contrib-
ute to all these processes now associated with atherosclerosis certainly
require further investigation.
Outcome and Quality of Life After Surgical and Endovascular Treat-
ment of Descending Aortic Lesions
Dick F, Hinder D, Immer FF, et al. Ann Thorac Surg 2008;85:1605-13.
Conclusion: Long-term quality of life (QOL) is reduced after thoracic
aortic repair. Thoracic endovascular aneurysm repair (TEVAR) patients do
not score higher in QOL compared with open repair patients.
Summary: Health-related QOL is now regarded as an important
variable in the evaluation of any invasive treatment. A small series of QOL
assessments after open aortic repair (OAR) for thoracic aortic pathologies
have found that QOL is impaired after OAR. Studies focusing on abdominal
aortic aneurysm repair have found the QOL is still impaired after endovas-
cular repair of abdominal aortic aneurysms. Similar data are lacking in
patients treated with TEVAR.
The aim of this single-center series was to assess outcome and postop-
erative long-term QOL in patients treated for a variety of thoracic aortic
pathologies by OAR or TEVAR. The results were compared with standard
populations adjusted for age and sex. The study is essentially a post hoc
analysis of a prospectively maintained database. Between January 2001 and
December 2005, 136 patients with a surgical problem of the descending
thoracic aorta were treated at the authors’ institution. Excluded from further
analyses were 14 patients because of concurrent involvement of the ascend-
ing aorta. Fifty-two patients underwent TEVAR and 70 underwent OAR.
Mean follow-up was 34  18 months. End points were perioperative and
late mortality and long-term QOL. QOL was assessed by the Short Form
36-Item Health Survey (SF-36) and the Hospital Anxiety and Depression
Score questionnaires.
TEVAR patients were older than the OAR patients (69  10 vs 62 
15 years; P  .002). Operative mortality did not differ between patients
treated with OAR (9%) and TEVAR (8%; P  .254), and long-term
mortality was similar. Overall QOL scores were 93 (range, 63-110) for OAR
and 83 (range, 60-112) for TEVAR. The QOL scores adjusted for age and
sex in a healthy population range from 85 to 115.
Comment: The results of this study are a bit surprising. However, the
patients were not randomized and the demographics of the TEVAR vs OAR
groups suggest a selection bias favoring entry into the TEVAR arm for
patients aged 65 years and for those with disease confined to the thorax
and those presenting with an emergency situation. These differences in the
baseline characteristics of the patients led the authors to compare their QOL
results with an age- and sex-adjusted standard population rather than to
compare the OAR patients directly with the TEVAR patients. Another
selection bias may result because patients with higher levels of pre-existing
depression and anxiety may be offered the less invasive procedure. Surpris-
ingly, QOL scores in the OAR patients were within the normal range. Those
of the TEVAR were lower compared with the normalized population. The
findings parallel those of the Dutch Randomised Endovascular Aneurysm
Management (DREAM) trial, which also found poor long-term QOL after
EVAR for abdominal aortic aneurysm (N Engl JMed 2005;352:2398-405).
One thing is becoming increasingly clear: underlying comorbidities inpatients with thoracic aortic disease make it rare to truly hit a “home run” in
patients with thoracic aortic pathology, irrespective of what therapy is used.
Patients with Peripheral Arterial Disease in the CHARISMA Trial
Cacoub PP, Bhatt DL, Steg PG, and the CHARISMA Investigators. Eur
Heart J 2009;30:192-201.
Conclusion: Dual antiplatelet therapy consisting of aspirin and clopi-
dogrel provides some benefit vs aspirin alone in patients with peripheral
arterial disease (PAD) with respect to rates of myocardial infarction and
hospitalization for ischemic events. There is an increase in minor bleeding.
Summary: In the Clopidogrel Versus Aspirin in Patients at Risk of
Ischaemic Events (CAPRIE) trial of 6452 patients, clopidogrel reduced the
risk of stroke, vascular death, or myocardial infarction by 23.8% more than
aspirin did in patients with PAD (Lancet 1996;348:1329-39). It is not
known, however, whether the combination of aspirin and clopidogrel is
more effective in patients with PAD in reducing cardiovascular events than a
single antiplatelet agent. That combination was evaluated in patients at risk
for cardiovascular end points in the Clopidogrel for High Atherothrombotic
Risk and Ischemic Stabilization, Management, and Avoidance (CHA-
RISMA) trial. CHARISMA enrolled patients with atheroembolic disease or
multiple risk factors for atheroembolic events. Dual antiplatelet therapy vs
aspirin alone produced only a nonsignificant 7.1% relative risk reduction in
myocardial infarction, cardiovascular death, or stroke during a median of 28
months (N Engl J Med 2006;354:1706-17).
This article is a post hoc analysis of the subset of patients with PAD
from CHARISMA. In CHARISMA there were 15,603 patients; of those,
2838 had symptomatic PAD and 258 were known to have asymptomatic
PAD. Symptomatic PAD was defined as the presence of intermittent clau-
dication with an ankle-brachial index (ABI) 0.85 or a history of claudica-
tion with a previous intervention. Asymptomatic PADwas defined as an ABI
0.9 in patients with multiple risk factors for atherosclerosis. In CHA-
RISMA, patients with PAD had rates of cardiovascular death, myocardial
infarction, and stroke (primary end point) that were higher than in those
without PAD (8.2% vs 6.8%, hazard ratio [HR], 1.25; 95% confidence
interval [CI], 1.08-1.44; P  .002). In the PAD patients, the primary end
point occurred at 7.6% in the clopidogrel plus aspirin group and at 8.9% in
the placebo plus aspirin group (HR, 0.85; 95% CI, 0.66-1.08; P .18). The
rate of MI was lower in the dual antiplatelet arm than in the aspirin arm
alone, at 2.3% vs 3.7% (HR, 0.63; 95% CI, 0.42-0.96; P .029). The rate of
hospitalization for ischemic events was also lower in the dual antiplatelet
group, at 16.5% vs 20.1% (HR, 0.81; 95% CI, 0.68-0.95; P  .001). Rates
of severe, fatal, or moderate bleeding did not differ between the groups.
Minor bleeding was increased in the dual antiplatelet group, at 34.4% vs
20.8% (odds ratio, 1.99; 95% CI, 1.69-2.34; P  .001).
Comment: With respect to cardiovascular risk, patients with PAD are
clearly the worst among the bad. Symptomatic and asymptomatic PAD
patients have a worse outcome with respect to the CHARISMA end points
than patients with coronary artery disease or with multiple risk factors for
vascular disease but without the actual development of detectable PAD. This
post hoc analysis shows some benefit of dual antiplatelet therapy in the PAD
patients, but it is certainly not the results dreams are made of. Given
increasing evidence that there are genetic determinants of responses to
antiplatelet therapies, whether that be aspirin or clopidogrel, it would seem
that further investigations should focus on identifying which patients with
PAD are likely to benefit the most from dual antiplatelet therapy and where
such benefit clearly exceeds the increased risk of bleeding.
Progression of Peripheral Arterial Disease Predicts Cardiovascular
Disease Morbidity and Mortality
Criqui, MH, Ninomiya JK, Wingard DL, et al. J Am Coll Cardiol 2008;52:
1736-42.
Conclusion: Progression of peripheral arterial disease (PAD), as de-
fined by a decline in ankle-brachial index (ABI)0.15, is associated with an
increased risk of all-cause mortality and cardiovascular mortality.
Summary: PAD is clearly associated with future cardiovascular disease
events and total mortality from cardiovascular disease. Other studies have
demonstrated that the ABI is a risk factor for cardiovascular mortality and is
independent of traditional cardiovascular disease risk factors. Studies exam-
ining the association of PADwith cardiovascular disease outcomes have used
ABI obtained at baseline and have not addressed the potential additional
significance of changes in ABI over time. The current study examined the
association between PAD as measured by ABI with cardiovascular disease
mortality and morbidity in 508 patients (449 men, 59 women) recruited
from two hospital vascular laboratories. Patients had to have had at least two
visits to the vascular laboratory, and ABI and cardiovascular disease risk
factors were measured at the second visit between 1990 and 1994. ABIs
from each patient’s earlier vascular laboratory examination (visit 1) were
abstracted from medical records. Hospital data and vital statistics were used
to track morbidity and mortality for 6 years after the second visit.
